77 indexable Genomics companies headquartered in Florida, United States, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $633M across 23 funded companies.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
Mel-Mont Medical
Developer of molecular screening devices for the early detection of infectious diseases |
$3M | — | Series A | Series A Dec 2025 | 4 | 2014 | ↑ Active |
| 2 |
Firebird Biomolecular Sciences
Provider of modified DNA as reagents for research, synthetic biology, and diagnostics |
$7.3M | — | Funding Raised | Grant (prize money) Jan 2025 | 9 | 2005 | ↑ Active |
| 3 |
VuEssence
Genome based diagnostic technology platform |
$2.7M | — | Seed | Seed Apr 2025 | 5 | 2010 | ↑ Active |
| 4 |
Deluge Biotechnologies
Developer of peptide-inspired constrained oligomers for the synthesis and screening of DNA-encoded |
$1.7M | — | Funding Raised | Grant (prize money) Mar 2025 | 15 | 2017 | ↑ Active |
| 5 |
Soilcea
Developing HLB-resistant citrus trees using CRISPR technology for Florida's citrus industry |
$750K | — | Seed | Grant (prize money) Mar 2025 | 3 | 2014 | ↑ Active |
| 6 |
NeoGenomics
Provider of cancer genetic diagnostic services |
$445.5M | — | Public | Post IPO Jan 2021 | 2,100 | 2002 | — |
| 7 |
Lakewood-Amedex
Developer of nano RNA gene silencing platform to develop targeted therapeutics for viral infections |
$36.2M | — | Public | Series C Jan 2021 | 11 | 2006 | — |
| 8 |
InflammX Therapeutics
Developer of therapeutics for ophthalmic disorders |
$28.5M | — | Series B | Series B Jan 2021 | 2 | 2005 | — |
| 9 |
Lacerta Therapeutics
Developer of adeno-associated virus for CNS diseases |
$32.8M | — | Deadpooled | Grant (prize money) Sep 2019 | 43 | 2015 | — |
| 10 |
InformedDNA
Provider of network of genetics experts to help patients and providers |
$19.2M | — | Series A | Series A Dec 2019 | 124 | 2007 | — |
| 11 |
GeneTx
Developer of a antisense oligonucleotide for treating a rare genetic disorder |
$20M | — | Acquired | Series A Aug 2019 | — | 2017 | — |
| 12 |
PositiveID Corporation
Developer of biological detection and diagnostics solutions |
$10.9M | — | Deadpooled | Series A Jan 2013 | 30 | 2001 | — |
| 13 |
NanoVir
Developer of DNA-targeting therapeutics to treat HPV |
$11.9M | — | Funding Raised | Grant (prize money) Jul 2010 | — | 2003 | — |
| 14 |
Cytonics
Developer of biologic therapies targeting molecular drivers of cartilage degradation |
$3.3M | — | Seed | Seed Jun 2019 | 8 | 2006 | — |
| 15 |
InteGen
Provider of cytogenetics, DNA FISH probes for research application |
$4.6M | — | Series A | Series A Oct 2018 | 4 | 2011 | — |
| 16 |
MDNA Life Sciences
Provider of genomic and molecular diagnostics based on the mitochondrial genome |
$1.2M | — | Acquired | Seed Jan 2019 | 8 | 2001 | — |
| 17 |
MicroGen Diagnostics
Provider of sequencing and molecular diagnostic services |
$1.6M | — | Seed | Seed Apr 2017 | 142 | 2011 | — |
| 18 |
Integrated Plant Genetics
Provider of genetic technologies for plant development and resistance |
$565.6K | — | Funding Raised | Grant (prize money) May 2015 | — | 1998 | — |
| 19 |
Cvergenx
Genomic informatics company personalizing radiation therapy with precision genomic radiation therapy platform |
$615.6K | — | Seed | Seed Dec 2015 | 3 | 2009 | — |
| 20 |
Rapid Genomics
Provider of DNA sequencing services for the improvement of crops and livestocks |
$300K | — | Acquired | Seed Oct 2015 | 30 | 2011 | — |
| 21 |
GeneLink BioSciences
Genome-based nutritional supplements |
$105K | — | Public | Post IPO Apr 2013 | 15 | 1994 | — |
| 22 |
Parallel Testing
App offering medication information |
$100K | — | Seed | Seed Apr 2017 | 4 | 2015 | — |
| 23 |
ProCare Diagnostics
Developer of next-generation diagnostic tests for prostate cancer |
$58K | — | Seed | Seed Oct 2016 | — | 2015 | — |
| 24 |
Ajuvis Labs
Provider of microbiome therapies and interventions for healthcare |
— | — | Unfunded | — | — | 2016 | — |
| 25 |
All About Truth DNA Testing
Provider of paternity and DNA testing services |
— | — | Deadpooled | — | — | 2010 | — |
| 26 |
Avatar DSS
Precision treatment support for cancer patients |
— | — | Funding Raised | — | — | 2015 | — |
| 27 |
axiVEND
Developers of instruments for liquid handling, and microarray |
— | — | Unfunded | — | 13 | 2019 | — |
| 28 |
beta analytic
Beta Analytic is a commitment to meet the demand of radiocarbon dating with rapid delivery and responsiveness to customer needs. |
— | — | Private | — | 55 | 1979 | — |
| 29 |
Biom Pharmaceuticals
Developer of probiotic products for medical applications |
— | — | Unfunded | — | 8 | 2016 | — |
| 30 |
Boca Scientific
Provider of molecular biology and immunology reagents and kits |
— | — | Unfunded | — | 7 | 2002 | — |
| 31 |
Body Science
Provider of genetic based personalised treatment |
— | — | Unfunded | — | — | 2010 | — |
| 32 |
Cambridge Diagnostic Technologies
Provider of molecular diagnostic tests and services |
— | — | Deadpooled | — | — | 2015 | — |
| 33 |
Chromox
DTC DNA testing services |
— | — | Deadpooled | — | — | 2012 | — |
| 34 |
ClarityX
Provider of gene-based medication testing kit for individuals and healthcare providers |
— | — | Unfunded | — | — | 2021 | — |
| 35 |
Coral Biotechnology
Provider of genomics services and manufactures robotics-based solutions |
— | — | Unfunded | — | — | 2016 | — |
| 36 |
D2 Laboratories
Provider of various molecular diagnostics, pharmacogenomic, and drug tests |
— | — | Deadpooled | — | — | 2014 | — |
| 37 |
Discidium Biosciences
PCR-based assays for the detection of ART resistance |
— | — | Deadpooled | — | — | 2015 | — |
| 38 |
DNA Labs International
Provider of forensic DNA testing services |
— | — | Unfunded | — | 74 | 2004 | — |
| 39 |
DNA Testing Solutions
Provider of forensic, legal, and ancestral DNA testing |
— | — | Unfunded | — | — | 2001 | — |
| 40 |
DNA/GPS
Developer of a genomic-based system for diagnoses of systemic diseases |
— | — | Acqui-Hired | — | — | — | — |
| 41 |
Elite Epigenetics
Provider of DNA tests and personalized nutrition plans |
— | — | Unfunded | — | — | 2020 | — |
| 42 |
Encrypgen
Provider of blockchain security for genomic data |
— | — | Acquired | — | 7 | 2017 | — |
| 43 |
Etta
Point of care multiplexed molecular diagnostic solutions |
— | — | Acqui-Hired | — | 3 | 2015 | — |
| 44 |
EvolveGene
Provider of genetic testing for fertility and prenatal screening |
— | — | Acqui-Hired | — | 9 | 2015 | — |
| 45 |
EvolveGene
DNA test kits for fertility screening |
— | — | Deadpooled | — | — | 2000 | — |
| 46 |
First Coast Testing Services
Provider of a range of DNA testing services |
— | — | Unfunded | — | — | 2001 | — |
| 47 |
Flyght Wellness Club
Provider of holistic wellness programs for women. It offers a five-step method incorporating mindfulness, meditation, and practical techniques to promote emotional well-being and self-awareness. Programs focus on building sustainable habits for balanced living, addressing areas such as gratitude, presence, and biodecoding to identify emotional roots of physical symptoms. A mobile application supports continued wellness practice. |
— | — | Unfunded | — | — | 2021 | — |
| 48 |
Gene2Know
Provider of pharmacogenomics services for personalized medicine |
— | — | Deadpooled | — | — | 2014 | — |
| 49 |
Genes Advice
Provider of genetic testing for medications compatibility |
— | — | Deadpooled | — | — | 2017 | — |
| 50 |
GeneWize Life Sciences
Online retailer of nutritional supplements |
— | — | Unfunded | — | — | 2008 | — |
Developer of molecular screening devices for the early detection of infectious diseases. The company develops a diversified portfolio of proprietary technologies and medical devices for the early identification of DNA and RNA virus-related pathologies. The product portfolio includes XytoTest and Anal test for cervical cancer, and HR-HPV DNA detection. Also, offers in-vitro diagnostic tests for the detection of HPV in
Provider of modified DNA as reagents for research, synthetic biology, and diagnostics. The company's products include reversible terminators (oxime blocked and disulfide-linked tags), artificially expanded genetic information systems, modified nucleosides, phosphoramides, triphosphates, and polymerases, and Self-Avoiding Molecular Recognition Systems (a species of DNA that can bind via simple rules to natural DNA but
VuEssence is developing diagnostic technology platforms for the treatment of stroke and neurological conditions. The company is developing diagnostic devices which use molecular analysis based on human genome and transcriptome data for the detection and management of stroke.
Developer of peptide-inspired constrained oligomers for the synthesis and screening of DNA-encoded. The company uses macrocyclic PICCO molecules that involved in the binding process of protein-protein interaction regions and allosteric sites. It also uses a novel FACS-based technology that maintains each molecule in the library & promotes isolation of selective ligands.
Developing HLB-resistant citrus trees using CRISPR technology for Florida's citrus industry. This innovative company focuses on restoring the natural defenses of citrus trees against Huanglongbing (HLB), a devastating disease. Through precision breeding and collaboration with the University of Florida, they are creating new citrus varieties that exhibit reduced disease levels and vigorous growth. Their technology off
Provider of cancer genetic diagnostic services. The company operates a network of cancer-focused testing labs, which is engaged in providing testing services to pathologists, oncologists, and other laboratories. The company provides services for cancer cytogenetics, hematologic and solid tumor FISH testing, 10-color flow cytometry, and nearly 100 molecular oncology tests comprising the most comprehensive combination
Developer of nano RNA gene silencing platform to develop targeted therapeutics for viral infections. The company's lead nanoRNA product, Influ-RNA, is an anti-influenza agent. The company is also developing drugs and has lead candidates for pneumonia in cystic fibrosis patients, chronic wounds, chronic otitis media, and implant- and catheter-associated infections.
Developer of therapeutics for ophthalmic disorders. It offers Xiflam an orally administered NLRP3 inflammasome inhibitor to inhibit the pathological Cx43 hemichannel and modulate the activation of the inflammasome. It is focused on the ophthalmic indications of diabetic macular edema, age-related macular degeneration, and geographic atrophy.
Lacerta Therapeutics is a developer of adeno-associated virus (AAV) vectors for treating CNS diseases and lysosomal storage diseases. The company has developed proprietary capsid variants and scalable vector manufacturing platform. It has developed AAV gene therapies for Pompe disease, Sanfilippo syndrome type B, aromatic L-amino acid decarboxylase deficiency, neurodegenerative proteinopathies, spinocerebellar ataxia
Provider of network of genetics experts to help patients and providers. The website provides information about the genetic counseling services provided by InformedDNA to both consumers and medical providers and allows them to book an appointment.
GeneTx Biothereputics (a subsidiary of the Foundation for Angelman Syndrome Therapeutics) is developing therapeutics for treating Angelman syndrome (AS). The company has developed GTX-102, an antisense oligonucleotide which is used for targeted therapy for treating the rare genetic disorder that causes developmental delay, impaired motor function, loss of speech, and epilepsy.
Developer of biological detection and diagnostics solutions. The company focused on the development of microfluidic systems M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) that analyzes air samples for the detection of biological airborne threats in the form of bacteria, viruses, and toxins.
HHS
United States Department of Agriculture
Anthem
Aspen Capital
Biosciences Research & Commercialization Center
Boma Investments
CDH Ventures
Canadian Imperial Bank of Commerce
Diaceutics
Domain Associates
Domain Russia Investments
Edge
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-23.
